Overview
VRAX market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 0.454900
- H
- 0.487300
- L
- 0.454900
- C
- 0.487300
- Vol
- 600.00
Daily history from Jul 21, 2022
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $0.45
- Previous Close
- $0.44
- Day High
- $0.49
- Day Low
- $0.45
- 52 Week High
- $21.75
- 52 Week Low
- $0.42
- 7 Day Return
- -19.13%
- 30 Day Return
- -65.56%
- 90 Day Return
- -86.00%
- 1 Year Return
- -95.87%
- Daily Notional Volume
- $292.4 Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$12.64 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.63 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -40,416.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.50 – $21.75 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $833K · P/B 0.26 · P/S 67.02.